Investing.com··Nathan ReiffTrump's Psychedelic Order Ignites Biotech Rally, But Valuations Raise Caution
Trump's April 2026 executive order grants FDA priority vouchers to psychedelic biotech firms, triggering stock surges for Compass Pathways, AtaiBeckley, and Definium Therapeutics amid speculative valuations.
DFTXCMPSPSILbiotechclinical trials